Berglund, Hanna
Salomonsson, Sara Lundsten
Mohajershojai, Tabassom
Gago, Fernando Jose Ferrer
Lane, David P.
Nestor, Marika http://orcid.org/0000-0003-4662-3142
Funding for this research was provided by:
Barncancerfonden (PR2020-0023)
Vetenskapsrådet (2020-01377)
Cancerfonden (CAN 20 0191, CAN 21 1534)
Stiftelsen Ulf Lundahls minnesfond
Uppsala University
Article History
Received: 21 June 2023
Accepted: 28 September 2023
First Online: 12 October 2023
Declarations
:
: The authors report no relevant conflicts of interest for the submitted work. David P. Lane has received support from Merck, Ipsen and Asian. David P. Lane is involved in a collaborative project with Merck on macrocyclic peptides and have a patent issued (WO2014055039A1) on Peptides and Methods for Treating Cancer. Marika Nestor is a co-founder and shareholder of Akiram Therapeutics. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.